PixarBio Corporation's Dr. Jason Criscione Promoted To Chief Technology Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation today announced that Jason Criscione, PhD, has been promoted to Chief Technology Officer. Since March 2014, Dr. Criscione has led the development and translation of PixarBio's drug delivery platform. "Combining key fields of immunotherapy, drug delivery and materials science know how, Jason led the design, development, and clinical translation of our biomaterials based system for sustained, locally delivered therapeutic interventions for a multitude of neurological indications," said PixarBio CEO Frank Reynolds.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.